Prostate cancer screening in Europe

The Lancet

Volumn 385, Issue 9977, 2015, Pages 1506-

  Ilic, Dragan ^a   Dahm, Philipp ^b  

^a MONASH UNIVERSITY   (Australia)

^b Minneapolis Veterans Affairs Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER SCREENING; CAUSE OF DEATH; EUROPE; HUMAN; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; MALE; MORTALITY; PROSTATIC NEOPLASMS;

HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84928409929     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60746-2     Document Type: Letter

References (5)

1. FH Schröder, J Hugosson, MJ Roobol et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up Lancet 384 2014 2027 2035
2. D Ilic, MM Neuberger, M Djulbegovic, P Dahm Screening for prostate cancer Cochrane Database Syst Rev 1 2013 CD004720.
3. M Djulbegovic, RJ Beyth, MM Neuberger et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials BMJ 341 2010 c4543
4. WC Black, DA Haggstrom, HG Welch All-cause mortality in randomized trials of cancer screening J Natl Cancer Inst 94 2002 167 173
5. HH Dubben Trials of prostate-cancer screening are not worthwhile Lancet Oncol 10 2009 294 298